There are 4 articles on this stock available only to PRO subscribers.
Fri, Feb. 28, 12:59 PM
- Endologix (ELGX -23.9%) shares plummet after the medical device maker reports mixed Q4 results and forecasts FY 2014 revenues below analyst consensus due to slow growth in U.S. device sales.
- ELGX sees FY 2014 GAAP EPS loss of $0.44-$0.31 vs. analyst consensus estimate of flat earnings, and revenues of $146M-$152M vs. $161M consensus.
- Oppenheimer downgrades shares to Perform from Outperform and lowers its price target to $16 from $20 on ELGX's disappointing 6%-10% 2014 U.S. growth forecast following 18% growth in 2013; the firm still sees Nellix as a long-term growth driver, but there's little to offset near-term U.S. uncertainty with no Nellix data read-outs expected this year and EU constraints not expected to be alleviated until Q4.
Fri, Feb. 28, 12:46 PM
Fri, Feb. 28, 9:14 AM
Thu, Feb. 27, 5:38 PM
May. 1, 2013, 9:10 AM
Jan. 28, 2013, 12:37 PMEndologix (ELGX +2.3%) presents data from its clinical trial of a totally percutaneous approach to endovascular abdominal aortic aneurysm repair, says the study demonstrated that the approach is non-inferior to surgical endovascular repair, and also has significantly reduced procedure times and time to hemostasis. The study also demonstrated positive trends toward lower blood loss, less need for pain medication, and shorter lengths of stay. | Comment!
Dec. 31, 2012, 2:59 PMEndologix (ELGX +1%) says its distribution partner in Japan, Cosmotec, has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the IntuiTrak Delivery System. The IntuiTrak System delivers ELGX's Powerlink anatomical fixation stent graft for the repair of abdominal aortic aneurysms. | Comment!
Jun. 12, 2012, 1:27 PMEndologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with management, the firm says ELGX's growth story remains intact and that abdominal aortic aneurysm market volumes and pricing remain solid. The firm thinks the Street is still underestimating the value of the company's Nelix treatment and reiterates a Buy on the stock. | Comment!
Feb. 2, 2012, 9:00 AMPremarket gainers: GMCR +21%. CEDC +21%. MTSN +15%. OMEX +10%. GPS +8%. CNQR +6%. EA +6%. CDNS +6%. QCOM +5%. ELGX +5%. GFA +5%. AUO +4%. KSS +4%. ZNGA +4%. IRE +4%. CMI +3%. K +3%. CPST +3%. JDSU +3%. MA +3%. RENN +3%.
Losers: SD -13%. ANF -12%. ANN -10%. NG -9%. BSX -6%. CI -6%. RCL -6%. UN -5%. MPW +4%. VIA -4%. UL -4%. CHKM -4%. SNE -4%. PCX -4%. PHM -3%. DOW -3%. ANZ -3%. CUK -3%. CCL -3%. NBG -3%. | Comment!
ELGX vs. ETF Alternatives
Endologix Inc develops, manufactures, markets & sells medical devices for the treatment of aortic disorders. Its main product is a stent graft & delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive EVAR or EVAS.
Other News & PR